{
    "info": {
        "nct_id": "NCT04768426",
        "official_title": "Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy",
        "inclusion_criteria": "1. Anatomic stage I - III triple-negative breast cancer at diagnosis\n2. Estrogen receptors (ER) and Progesterone receptors (PR) status <10%\n3. Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible.\n4. ≥ 18 years of age\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n6. All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy.\n7. No evidence of metastatic disease.\n8. A minimum 4-week wash out from previous chemotherapy treatment is required.\n9. Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3); Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)\n10. Adequate hepatic function: Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN. Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN\n11. Adequate renal function: Serum creatinine ≤ 1.5 x ULN; or calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula.\n12. Planned for 6 months or 8 cycles of adjuvant capecitabine.\n13. Women of childbearing potential (WOCBP) must have a negative pregnancy test.\n14. WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.\n15. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.\n16. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Metastatic breast cancer\n2. Has not had definitive surgical resection\n3. Pregnant or breastfeeding\n4. Has not completed definitive adjuvant radiation if planned\n5. Known human immunodeficiency virus (HIV) positivity or active hepatitis B or C.\n6. Investigational agents within 4 weeks of study initiation\n7. Inability to swallow oral medications",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "13. Women of childbearing potential (WOCBP) must have a negative pregnancy test.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) must have a negative pregnancy test.",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Residual disease following at least 4 cycles of neoadjuvant chemotherapy",
                    "criterion": "residual disease after neoadjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of neoadjuvant chemotherapy cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible",
                    "criterion": "receipt of investigational immunotherapy or targeted therapy during neoadjuvant phase",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Estrogen receptors (ER) and Progesterone receptors (PR) status <10%",
            "criterions": [
                {
                    "exact_snippets": "Estrogen receptors (ER) ... status <10%",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Progesterone receptors (PR) ... status <10%",
                    "criterion": "progesterone receptor (PR) status",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. A minimum 4-week wash out from previous chemotherapy treatment is required.",
            "criterions": [
                {
                    "exact_snippets": "A minimum 4-week wash out from previous chemotherapy treatment is required.",
                    "criterion": "washout period from previous chemotherapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. ≥ 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. No evidence of metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "No evidence of metastatic disease.",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Planned for 6 months or 8 cycles of adjuvant capecitabine.",
            "criterions": [
                {
                    "exact_snippets": "Planned for 6 months or 8 cycles of adjuvant capecitabine",
                    "criterion": "adjuvant capecitabine treatment",
                    "requirements": [
                        {
                            "requirement_type": "planned_duration",
                            "expected_value": [
                                "6 months",
                                "8 cycles"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Adequate renal function: Serum creatinine ≤ 1.5 x ULN; or calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Capable of giving signed informed consent",
                    "criterion": "informed consent capability",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol",
                    "criterion": "compliance with informed consent form and protocol",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0)",
                    "criterion": "clinically significant toxic effects of prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade (NCI CTCAE v5.0)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia and G2 neuropathy",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from resolution requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except alopecia and G2 neuropathy",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "Grade (NCI CTCAE v5.0)"
                            }
                        },
                        {
                            "requirement_type": "exclusion from resolution requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3); Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Anatomic stage I - III triple-negative breast cancer at diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Anatomic stage I - III ... at diagnosis",
                    "criterion": "anatomic stage of breast cancer at diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "triple-negative breast cancer",
                    "criterion": "breast cancer subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "triple-negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the study",
                                "for 3 months after the last dose"
                            ]
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "effective"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Adequate hepatic function: Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN. Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN.",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (Gilbert's syndrome exception)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Aspartate transaminase (AST) ... ≤ 2.5 x ULN",
                    "criterion": "aspartate transaminase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) ... ≤ 2.5 x ULN",
                    "criterion": "alanine transaminase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "Male participants ... must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.",
                    "criterion": "male participant contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after the last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.",
                    "criterion": "female partner contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after the last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "7. Inability to swallow oral medications",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Metastatic breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Metastatic breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "metastatic_status",
                            "expected_value": "metastatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Investigational agents within 4 weeks of study initiation",
            "criterions": [
                {
                    "exact_snippets": "Investigational agents within 4 weeks of study initiation",
                    "criterion": "use of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Has not completed definitive adjuvant radiation if planned",
            "criterions": [
                {
                    "exact_snippets": "Has not completed definitive adjuvant radiation if planned",
                    "criterion": "definitive adjuvant radiation",
                    "requirements": [
                        {
                            "requirement_type": "completion status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "plan status",
                            "expected_value": "if planned"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has not had definitive surgical resection",
            "criterions": [
                {
                    "exact_snippets": "Has not had definitive surgical resection",
                    "criterion": "definitive surgical resection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "5. Known human immunodeficiency virus (HIV) positivity or active hepatitis B or C.",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) positivity",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}